特邀产品简介:在护理点检测莱姆病抗体

M. Winters
{"title":"特邀产品简介:在护理点检测莱姆病抗体","authors":"M. Winters","doi":"10.1097/POC.0000000000000211","DOIUrl":null,"url":null,"abstract":"L yme disease is caused by an infection with the bacterium Borrelia burgdorferi. The bacteria is carried by the ticks and is transferred via the tick's bite. Lyme disease is estimated to be the most commonvector-borne illness in the United States. Diagnosis of the disease is challenging because of symptoms that can mimic other diseases. People treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Therefore, it is important to diagnose the illness early and accurately. Commercially available Lyme assays are designed to detect antibodies (either IgM, IgG, or IgM/IgG combined) in the patient's blood. The most commonly used assays require serum, which required processing of the patient's blood before testing. This processing step often requires the specimen to be sent to larger hospital and reference laboratories for testing. This lack of “near-patient” testing delays patient diagnosis and potential treatment. The Sofia 2 Lyme Fluorescent Immunoassay (FIA) eliminates the specimen processing requirement is the first and only test that can detect the antibodies to the B. burgdorferi bacteria with only a fingerstick. Because of its ease of use and diagnostic performance, the Sofia 2 test has been granted a Clinical Laboratory Improvement Amendments (CLIA) Waiver. This makes the test available in Physician's Offices and Urgent Care facilities for “near-patient” testing. With the new availability of a rapid and accurate result, providers can determine the next steps for treatment without delay.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":"55 8","pages":"95 - 96"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Invited Product Profile: Detecting Antibodies for Lyme Disease at the Point of Care\",\"authors\":\"M. Winters\",\"doi\":\"10.1097/POC.0000000000000211\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"L yme disease is caused by an infection with the bacterium Borrelia burgdorferi. The bacteria is carried by the ticks and is transferred via the tick's bite. Lyme disease is estimated to be the most commonvector-borne illness in the United States. Diagnosis of the disease is challenging because of symptoms that can mimic other diseases. People treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Therefore, it is important to diagnose the illness early and accurately. Commercially available Lyme assays are designed to detect antibodies (either IgM, IgG, or IgM/IgG combined) in the patient's blood. The most commonly used assays require serum, which required processing of the patient's blood before testing. This processing step often requires the specimen to be sent to larger hospital and reference laboratories for testing. This lack of “near-patient” testing delays patient diagnosis and potential treatment. The Sofia 2 Lyme Fluorescent Immunoassay (FIA) eliminates the specimen processing requirement is the first and only test that can detect the antibodies to the B. burgdorferi bacteria with only a fingerstick. Because of its ease of use and diagnostic performance, the Sofia 2 test has been granted a Clinical Laboratory Improvement Amendments (CLIA) Waiver. This makes the test available in Physician's Offices and Urgent Care facilities for “near-patient” testing. With the new availability of a rapid and accurate result, providers can determine the next steps for treatment without delay.\",\"PeriodicalId\":20262,\"journal\":{\"name\":\"Point of Care: The Journal of Near-Patient Testing & Technology\",\"volume\":\"55 8\",\"pages\":\"95 - 96\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Point of Care: The Journal of Near-Patient Testing & Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/POC.0000000000000211\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Point of Care: The Journal of Near-Patient Testing & Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/POC.0000000000000211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

莱姆病是由伯氏疏螺旋体感染引起的。这种细菌由蜱虫携带,并通过蜱虫的叮咬传播。据估计,莱姆病是美国最常见的媒介传播疾病。这种疾病的诊断具有挑战性,因为它的症状可以模仿其他疾病。在莱姆病的早期阶段接受适当抗生素治疗的人通常会迅速完全康复。因此,早期准确诊断疾病非常重要。市售的莱姆病检测方法用于检测患者血液中的抗体(IgM、IgG或IgM/IgG联合)。最常用的化验需要血清,这需要在检测前对患者的血液进行处理。这一处理步骤通常需要将标本送到较大的医院和参考实验室进行检测。缺乏“近患者”检测会延误患者的诊断和潜在的治疗。索菲亚2莱姆病荧光免疫分析(FIA)消除了标本处理要求,是第一个也是唯一一个仅用手指就能检测伯氏疏螺旋体细菌抗体的测试。由于其易于使用和诊断性能,Sofia 2测试已获得临床实验室改进修正案(CLIA)豁免。这使得该测试可以在医生办公室和紧急护理设施进行“近病人”测试。有了新的快速和准确的结果,提供者可以毫不拖延地确定下一步的治疗步骤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Invited Product Profile: Detecting Antibodies for Lyme Disease at the Point of Care
L yme disease is caused by an infection with the bacterium Borrelia burgdorferi. The bacteria is carried by the ticks and is transferred via the tick's bite. Lyme disease is estimated to be the most commonvector-borne illness in the United States. Diagnosis of the disease is challenging because of symptoms that can mimic other diseases. People treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Therefore, it is important to diagnose the illness early and accurately. Commercially available Lyme assays are designed to detect antibodies (either IgM, IgG, or IgM/IgG combined) in the patient's blood. The most commonly used assays require serum, which required processing of the patient's blood before testing. This processing step often requires the specimen to be sent to larger hospital and reference laboratories for testing. This lack of “near-patient” testing delays patient diagnosis and potential treatment. The Sofia 2 Lyme Fluorescent Immunoassay (FIA) eliminates the specimen processing requirement is the first and only test that can detect the antibodies to the B. burgdorferi bacteria with only a fingerstick. Because of its ease of use and diagnostic performance, the Sofia 2 test has been granted a Clinical Laboratory Improvement Amendments (CLIA) Waiver. This makes the test available in Physician's Offices and Urgent Care facilities for “near-patient” testing. With the new availability of a rapid and accurate result, providers can determine the next steps for treatment without delay.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信